Polynucleotides
Polynucleotides for enlarged pores: what does the 2026 trial show?
A small randomised trial measured changes in pore volume and texture after polynucleotide injections, but it does not prove that every visible pore will respond or identify the best treatment for every cause.
Visible pores do not have one cause
Pores are normal openings of hair follicles and cannot literally be erased. They may look more prominent because of oil production, reduced skin elasticity, follicle size, previous acne, sun exposure or the way light falls across uneven texture. More than one factor can be present, so the same treatment will not suit every person.
Consultation should distinguish enlarged pores from open comedones, active acne and depressed acne scars. These concerns can appear similar in photographs but may require different approaches. Polynucleotides are considered for gradual skin-quality change; they should not be presented as a substitute for treating active acne or as a guaranteed way to create poreless skin.
What did the new trial test?
A June 2026 pilot trial enrolled 30 adults with enlarged facial pores at one university hospital in Thailand. Each participant received the same polynucleotide treatment on both sides of the face over three sessions, four weeks apart. One side was treated with an intradermal needle technique and the other with a subdermal cannula technique.
The split-face design allowed each person to act as their own comparison, and the evaluator was blinded to the technique used. Researchers measured pore volume, texture, sebum and hydration and also collected clinician assessments, patient satisfaction, pain scores and adverse events through five months.
What improved—and what did not?
Both delivery approaches were followed by reductions in measured pore volume and improvements in skin texture. The needle side appeared to improve earlier, but there was no statistically significant difference between techniques. This means the study did not establish that one method was more effective than the other.
Sebum levels did not change significantly with either method, and the small increase in hydration was not statistically significant. This matters because oily skin is often assumed to be the reason for enlarged pores. The findings do not support claiming that polynucleotides reliably control oil production or provide a measurable hydration benefit in this setting.
Why the results need restraint
The study was small, single-centre and mainly involved women aged 23 to 43 with skin types III or IV. There was no untreated or placebo side, so it cannot separate the treatment effect from repeated needling, natural variation or other influences. Follow-up was also short for an injectable intended to support gradual skin change.
The researchers noted that no minimum clinically important difference has been established for pore volume. A statistically significant measurement may therefore not equal a change that every patient can see or considers worthwhile. The product was supplied and the study supported by its manufacturer, although the authors stated that the sponsor did not control the design or analysis.
Technique changes the experience as well as the result
The cannula approach produced lower average pain scores. Bruising occurred with both methods and settled within one week in the trial. Temporary itchy red papules were also recorded, more often with the needle technique. These findings relate to the combined depth and delivery approach, not simply to choosing a needle or cannula in isolation.
In ordinary practice, raised injection points, redness, tenderness, swelling and bruising may occur. Less common problems include infection, persistent inflammation, lumps or an allergic reaction. Increasing pain, heat, spreading redness, discharge, fever, unusual skin colour or worsening swelling needs prompt clinical advice; severe or rapidly progressing symptoms require urgent medical help.
Individual assessment comes before a treatment course
Three sessions were used in this trial, but that does not make three appointments a universal prescription. The exact product, injection plan, skin condition, cause of pore prominence, previous reactions, allergies, medicines, pregnancy or breastfeeding and other planned procedures must be considered individually. Active infection or inflammation may mean postponing treatment.
The General Medical Council requires cosmetic interventions to be based on current evidence and expects clear discussion of risks, alternatives and follow-up. A useful plan should define the concern, use consistent photographs and agree how improvement will be judged. Depending on the cause, skincare, acne management, another procedure or no treatment may be more appropriate.